Last reviewed · How we verify

Intraoperative continuous insulin infusion

Rabin Medical Center · FDA-approved active Small molecule

Intraoperative continuous insulin infusion maintains tight perioperative glycemic control by delivering insulin intravenously during surgery to prevent hyperglycemia-related complications.

Intraoperative continuous insulin infusion maintains tight perioperative glycemic control by delivering insulin intravenously during surgery to prevent hyperglycemia-related complications. Used for Perioperative glycemic control in surgical patients, particularly those undergoing cardiac surgery or major procedures.

At a glance

Generic nameIntraoperative continuous insulin infusion
SponsorRabin Medical Center
Drug classInsulin (human recombinant)
TargetInsulin receptor
ModalitySmall molecule
Therapeutic areaPerioperative care / Endocrinology
PhaseFDA-approved

Mechanism of action

This is a clinical protocol rather than a novel drug entity—it involves continuous IV insulin administration during the intraoperative period to maintain blood glucose within a target range (typically 80–180 mg/dL). Tight glycemic control during surgery reduces surgical site infections, improves wound healing, and decreases postoperative morbidity by mitigating the stress hyperglycemia response and its inflammatory consequences.

Approved indications

Common side effects

Key clinical trials

Primary sources

Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.

SourceUsed for
ClinicalTrials.govTrial enrolment, design, endpoints, results

Competitive intelligence

For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape: